Medico Remedies Ltd (MEDICO)

📊 Quarterly Results (₹ Cr)

Revenue has shown sequential improvement, rising from ₹38 lakhs in June 2025 to ₹69 lakhs in June 2026, while profitability remains volatile, with operating margins fluctuating between 3.7% and 11.2%. Net profit increased from ₹2 lakhs to ₹3 lakhs over the same period, though absolute levels remain low. The upward trend in quarterly revenue suggests incremental growth, but profitability has not translated into consistent margin expansion, reflecting operational sensitivity. The company’s financial trajectory aligns with management’s focus on incremental expansion rather than scale-driven profitability, with reinvestment priorities evident in capital allocation decisions.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or profitability targets, but the reappointment of key directors and remuneration increases signal confidence in continuity and governance stability. The company emphasized its focus on manufacturing expansion, risk management, and compliance with SEBI and MCA regulations in the Annual Report. With no dividend declared and reinvestment of profits, management appears committed to sustaining long-term growth through operational refinement and leadership stability rather than shareholder distributions.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a conservative capital structure with equity of ₹17 crores and reserves growing from ₹46 to ₹59 crores over two years, indicating retained earnings. Borrowings remain low at ₹19 crores as of March 2026, down from ₹14 crores in March 2025, suggesting deleveraging or minimal reliance on debt. Total assets have grown steadily from ₹120 to ₹153 crores, in line with revenue expansion. This financial profile supports a strategy of organic reinvestment and prudent capital management, with limited need for external financing.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 61.38% across all reporting periods, indicating strong control and alignment with long-term interests. Foreign institutional investor (FII) holding is negligible, fluctuating between 0.03% and 0.49%, while Domestic Institutional Investor (DII) participation is minimal or absent. The number of shareholders has slightly declined, from 18,503 to 15,863, suggesting retail dilution or consolidation. No significant selling by promoters or institutions is evident, reinforcing stability in ownership structure.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Heavy reliance on key managerial personnel, including the Mehta family, whose departure could disrupt operations. 2. Exposure to foreign exchange volatility, as highlighted in risk disclosures, which could impact input costs and margins. 3. Operational challenges in manufacturing, mentioned as a material risk, may constrain scalability. 4. Regulatory changes in the pharmaceutical sector could affect compliance costs and product approvals. These risks are intertwined with governance and execution capabilities, making leadership continuity critical.

📋 Recent Filings

• 🟡 voting results2026-09-23Medico Remedies held its 32nd AGM on 22 September 2026, approving all seven resolutions including adoption of financial statements, appointments of di…
• 🟡 Board Meeting2026-09-22Medico Remedies held its 32nd AGM on 22 September 2026 via video conference, adopting audited FY2026 financials and approving key director reappointme…
• 🟡 Board Meeting2026-08-29Medico Remedies announced that its share register will close from 16 to 22 September 2026 for record purposes, with the 32nd Annual General Meeting sc…
• 🔴 annual report2026-08-29Medico Remedies Limited submitted its Annual Report 2025-26 along with notice of the 32nd AGM on August 29, 2026. The report covers full-year performa…
• 🔴 annual report2026-08-29Medico Remedies Limited submitted its Annual Report 2025-26 to BSE on 29 August 2026, covering FY ending 31 March 2026. The report includes AGM notice…
• 🟡 Board Meeting2026-08-13Medico Remedies announced board approval of quarterly results for June 2026, reappointments of Rishit Mehta and Haresh Mehta as directors, increased r…
• Announcement2026-08-05Medico Remedies Limited announced it received a government supply order worth approximately USD 1406450 (about INR 13.38 crores) from PROMESE/CAL in t…
• 🔴 Announcement2026-06-29Medico Remedies Limited announced that CRISIL Ratings reaffirmed its long-term bank facilities rating at Crisil BBB-/Stable for Rs. 19 crore and short…
• Announcement2026-06-03Medico Remedies Limited disclosed it received a Show Cause of Penalty notice from NSE and BSE on 20 May 2026 for alleged non-compliance with Regulatio…
• 🔴 Announcement2026-06-01No summary available

🧠 Analyst's Read

Medico Remedies exhibits governance stability and financial prudence, with a mature promoter-led structure and reinvestment-oriented strategy. Investors should monitor execution of manufacturing initiatives and the outcome of the upcoming AGM vote on director reappointments and remuneration. The absence of dividends and low institutional interest suggest limited near-term upside, but the company may offer steady, if modest, long-term value if operational risks are managed effectively.

Based on filing content and financial data. Not a recommendation.